Genetically proxied GIP pathway links to lower fracture risk
Scaled to lower BMI, genetically proxied GIP-GIPR perturbation tracked with lower odds of major osteoporotic fractures (OR 0.80) and spine-and-hip fractures (OR 0.68).
Diabetes, Obesity & Metabolism
Researchers analyzed genetic and health records from 401,983 unrelated UK Biobank participants to test how incretin pathway perturbation affects bone health. The team performed drug-target Mendelian randomization using cis genetic variants near GIP, GIPR, GCG, and GLP1R, scaling instruments to lower BMI or lower HbA1c.
GIP-GIPR perturbation was associated with lower odds of major osteoporotic fractures (OR 0.80, 95% CI 0.66–0.98) and spine-and-hip fractures (OR 0.68, 95% CI 0.49–0.94) when scaled to lower BMI. Similar patterns occurred when scaled to HbA1c. In Cox analyses, GIP-GIPR genetic risk scores were associated with a lower risk of major osteoporotic and combined spine-and-hip fractures. Genome-wide liability to lower BMI or HbA1c did not mirror these associations.
Why it matters
Osteoporotic fractures represent a major contributor to disability and loss of independence with age. These genetic findings support skeletal safety evaluations for therapies targeting GIP receptors.
Caveats
The findings rely on genetic proxies rather than randomized drug exposures and did not show an association with estimated bone mineral density. In addition, estimates for the GCG-GLP1R pathway were imprecise.
The paper
Genetically Proxied GIP-GIPR Pathway Perturbation and Fracture Risk
Manchester Academic Health Science Centre
Diabetes, Obesity & Metabolism · 29 Sep 2026